These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20123556)

  • 1. Neuroprotection in Parkinson's disease.
    Schapira AH
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S41-3. PubMed ID: 20123556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
    Löhle M; Reichmann H
    J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME
    J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why have we failed to achieve neuroprotection in Parkinson's disease?
    Olanow CW; Kieburtz K; Schapira AH
    Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotection in Parkinson's disease: clinical trials.
    Stocchi F; Olanow CW
    Ann Neurol; 2003; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurobiology and treatment of Parkinson's disease.
    Schapira AH
    Trends Pharmacol Sci; 2009 Jan; 30(1):41-7. PubMed ID: 19042040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future strategies for neuroprotection in Parkinson's disease.
    Schapira AH
    Neurodegener Dis; 2010; 7(1-3):210-2. PubMed ID: 20224288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
    Prediger RD
    J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].
    Linazasoro G; Sesar A; Valldeoriola F; Compta Y; Herrero MT; Martínez Castrillo JC; López Lozano JJ; Bergaretxe A; Vela L; Fernández JM; Castro A; Kulisevski J; Lezcano E; Vaamonde J; López Del Val J; Chacón J; Vivancos F; Luquin R; Aguilar M; Burguera JA; Salvador C; Menéndez Guisasola L; Catalán MJ; Mir P; Campos V; Grandas F; Mínguez A; Balaguer E; Yáñez R; Leiva C; García Ruiz P; Cubo E
    Neurologia; 2009 Mar; 24(2):113-24. PubMed ID: 19322690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM; Ravina B
    Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovering neuroprotection in Parkinson's disease, or getting to haphazard.
    Kieburtz K
    Mt Sinai J Med; 2010; 77(6):700-6. PubMed ID: 21105130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotection for Parkinson's disease.
    LeWitt PA
    J Neural Transm Suppl; 2006; (71):113-22. PubMed ID: 17447422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K
    Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke CE
    Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A global view of Parkinson's disease pathogenesis: implications for natural history and neuroprotection.
    Linazasoro G
    Parkinsonism Relat Disord; 2009 Jul; 15(6):401-5. PubMed ID: 19346152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in environmental epidemiology.
    Tanner CM
    Mov Disord; 2010; 25 Suppl 1():S58-62. PubMed ID: 20187243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What's in the pipeline for the treatment of Parkinson's disease?
    Sommer DB; Stacy MA
    Expert Rev Neurother; 2008 Dec; 8(12):1829-39. PubMed ID: 19086879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
    Kalda A; Yu L; Oztas E; Chen JF
    J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.